Arfendazam
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.694 |
| Chemical and physical data | |
| Formula | C18H17ClN2O3 |
| Molar mass | 344.792 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Arfendazam (INN)[1] is a drug which is a benzodiazepine derivative. Arfendazam is a 1,5-benzodiazepine, with the nitrogen atoms located at positions 1 and 5 of the diazepine ring, and so is most closely related to other 1,5-benzodiazepines such as clobazam.
Arfendazam has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, but is a partial agonist at GABAA receptors, so the sedative effects are relatively mild and it produces muscle relaxant effects only at very high doses.[2][3]
Arfendazam produces an active metabolite lofendazam, which is thought to be responsible for part of its effects.[4]
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
See also
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances. Proposed International Nonproprietary Names (Prop. INN): List 39. Supplement to WHO Chronicle, 1978, Vol. 32, No. 3 (March)" (PDF). World Health Organization. p. 3. Retrieved 4 December 2015.
- ^ Müller E. Benzodiazepine receptor interactions of arfendazam, a novel 1, 5-benzodiazepine. Pharmacopsychiatry 1985, (18):10-11.
- ^ Müller WE, Groh B, Bub O. In vitro and in vivo studies of the mechanism of action of arfendazam, a novel 1, 5-benzodiazepine. Pharmacopsychiatry 1986, (10):314-315.
- ^ J. Adrien, F. Albani, A. Baruzzi, M. Berger, E.O. Bixler, A.A. Borbeley, D.G. Dikeos, R. Drucker-Colin, R. Fritsch Montero, Y. Hishikawa, S. Inoue, A. Kales, E. Lugaresi, H. Merchant-Nancy, J.M. Monti. The Pharmacology of Sleep. Springer. ISBN 978-3-540-58961-7
| This sedative-related article is a stub. You can help Wikipedia by expanding it. |